Literature DB >> 21841459

Pharmacologic treatment of apathy in dementia.

Karen Berman1, Henry Brodaty, Adrienne Withall, Katrin Seeher.   

Abstract

Apathy in patients with dementia is common, underrecognized, and undertreated. We sought to improve understanding of the pharmacologic treatment of apathy in dementia by performing a systematic literature review of studies that used apathy outcome scales to document results of pharmacologic treatments for apathy. There is limited evidence of efficiency of pharmacotherapy for treatment of apathy in dementia. The best results were found for acetylcholinesterase inhibitors. There was some evidence of efficacy for memantine, but less evidence of efficacy for stimulants, calcium antagonists, and antipsychotics. There was no evidence to support the use of antidepressants or anticonvulsants. The research quality of studies was modest. Recommendations for standardizing research and for holistic evaluation and treatment are provided.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21841459     DOI: 10.1097/JGP.0b013e31822001a6

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  21 in total

1.  Neuroprotective evidence of alpha-lipoic acid and desvenlafaxine on memory deficit in a neuroendocrine model of depression.

Authors:  Caren Nádia Soares de Sousa; Lucas Nascimento Meneses; Germana Silva Vasconcelos; Ingridy da Silva Medeiros; Márcia Calheiros Chaves Silva; Fayçal Mouaffak; Oussama Kebir; Cláudio Manuel Gonçalves da Silva Leite; Manoel Cláudio Azevedo Patrocinio; Danielle Macedo; Silvânia Maria Mendes Vasconcelos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-05-07       Impact factor: 3.000

2.  State of the Science: Apathy As a Model for Investigating Behavioral and Psychological Symptoms in Dementia.

Authors:  Lauren Massimo; Helen C Kales; Ann Kolanowski
Journal:  J Am Geriatr Soc       Date:  2018-04       Impact factor: 5.562

Review 3.  Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease.

Authors:  Christoph Mueller; Anto P Rajkumar; Yi Min Wan; Latha Velayudhan; Dominic Ffytche; Kallol Ray Chaudhuri; Dag Aarsland
Journal:  CNS Drugs       Date:  2018-07       Impact factor: 5.749

4.  Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis.

Authors:  Taro Kishi; Yuki Matsuda; Nakao Iwata
Journal:  Psychopharmacology (Berl)       Date:  2017-05-15       Impact factor: 4.530

5.  [Antipsychotics for treatment of neuropsychiatric disorders in dementia].

Authors:  H-J Gertz; G Stoppe; B Müller-Oerlinghausen; L G Schmidt; C Baethge; C Hiemke; K Lieb; T Bschor
Journal:  Nervenarzt       Date:  2013-03       Impact factor: 1.214

Review 6.  Neuropsychiatric Symptoms in Mild Cognitive Impairment.

Authors:  Damien Gallagher; Corinne E Fischer; Andrea Iaboni
Journal:  Can J Psychiatry       Date:  2017-03       Impact factor: 4.356

7.  Treatment and Management of Dementia Due to Alzheimer's Disease.

Authors:  Jennifer Rose V Molano; Robin Bratt; Rhonna Shatz
Journal:  Curr Treat Options Neurol       Date:  2015-08       Impact factor: 3.598

8.  Motivational Impairment is Accompanied by Corticoaccumbal Dysfunction in the BACHD-Tg5 Rat Model of Huntington's Disease.

Authors:  Natalie E Zlebnik; Iness Gildish; Thibaut Sesia; Aurelie Fitoussi; Ellen A Cole; Brian P Carson; Roger Cachope; Joseph F Cheer
Journal:  Cereb Cortex       Date:  2019-12-17       Impact factor: 5.357

Review 9.  Pharmacologic treatment of depression in the elderly.

Authors:  Christopher Frank
Journal:  Can Fam Physician       Date:  2014-02       Impact factor: 3.275

10.  Apathy, poor verbal memory and male gender predict lower psychosocial functioning one year after the first treatment of psychosis.

Authors:  Ann Faerden; Elizabeth Ann Barrett; Ragnar Nesvåg; Svein Friis; Arnstein Finset; Stephen R Marder; Joseph Ventura; Ole A Andreassen; Ingrid Agartz; Ingrid Melle
Journal:  Psychiatry Res       Date:  2013-03-13       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.